ReviewNpj imaging2025
Through every lens: assessing the impact of chemical modifications on antibody-conjugates using in vivo imaging.
Review in Npj imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag-Dyes.Research square · 2026Article
- Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chemical modification of monoclonal antibodies (mAbs) and their fragments gives rise to imaging probes and targeted therapies. Depending on the isotope used, radiolabeled mAbs enable positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging and can also be applied as cytotoxic therapies. Fluorescent mAb conjugates are used for a range of preclinical applications with clinical utility for intraoperative visualization of tumors. Antibody-drug conjugates (ADCs) enhance the therapeutic efficacy of mAbs and are the topic of extensive clinical development. In all these cases, chemical modifications can significantly affect mAb tumor targeting and clearance. Whole-body imaging techniques provide crucial insights into the in vivo consequences of these changes by directly tracking antibody conjugate distribution and clearance. This review examines in vivo imaging studies that compare "parental" and "modified" mAbs imaged under identical conditions to assess the effects of the cargo itself (e.g. fluorophore, chelator, drug), as well as the chemical conjugation methods. Additionally, we also describe studies that evaluate alternative strategies, including pretargeting, Fc modifications and pre- or co-dosing strategies that seek to tune the biodistribution of a given conjugate. Overall, we highlight the critical role of imaging in characterizing the in vivo performance of mAb conjugates, underscoring how these insights can inform both therapeutic efficacy and toxicity, and enable clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.